Busy Philipps Urges Women to Manage ADHD This Fall with Supernus Pharmaceuticals and Qelbree

Ahead of ADHD Awareness Month, Busy Philipps, a well-known actress, author, podcaster, late-night host, and mother, is sharing her personal story about her ADHD diagnosis and her experience with Qelbree® (viloxazine extended-release capsules) to inspire and support women dealing with ADHD. ADHD often manifests differently in women compared to men, making it harder to identify and frequently leaving women undiagnosed and untreated.

Busy Philipps is teaming up with Supernus Pharmaceuticals to talk about her ongoing journey with ADHD and the benefits she has experienced from using Qelbree. The fall season is an opportune time for many adults to return to their regular routines or embark on new beginnings. However, for the roughly 10 million adults in the U.S. living with ADHD, managing symptoms such as inattention and hyperactivity can complicate this transition.

Busy Philipps aims to empower individuals, particularly women, by encouraging them to seek medical advice and explore treatment options for their condition. She reflects on her own challenges with unmanaged ADHD, describing how she would often start tasks without finishing them, feel restless, and have difficulty multitasking due to frequent distractions. Now that she is taking Qelbree, she finds her symptoms more manageable and wishes she had taken control of her ADHD sooner. By sharing her experience, she hopes to raise awareness about ADHD and assist others in finding effective treatment options.

Qelbree is a unique, once-daily, non-stimulant treatment for patients aged six and older with ADHD. It is also the first non-stimulant medication approved for adults with ADHD in two decades. Unlike stimulants, Qelbree does not have a risk of abuse or misuse and can be refilled without needing a new prescription every month.

Supernus Pharmaceuticals is dedicated to offering treatment options and educational resources to help individuals manage their ADHD symptoms. Jack A. Khattar, President and CEO of Supernus Pharmaceuticals, expresses gratitude for Busy Philipps's support and her willingness to share her ADHD journey and positive experience with Qelbree, particularly as ADHD Awareness Month approaches.

For those interested in learning more about Qelbree, it is advised to consult their healthcare providers. Qelbree is a prescription medication intended for the treatment of ADHD in both adults and children aged six and older, with safety information indicating that it may increase suicidal thoughts and actions in some individuals, especially during the first few months of treatment or when the dosage is changed. It is crucial for patients and caregivers to monitor moods, behaviors, thoughts, and feelings, and report any sudden changes to a healthcare provider immediately.

Patients should not take Qelbree if they are on monoamine oxidase inhibitors (MAOIs) for depression or have recently discontinued MAOIs. Additionally, they should avoid certain medications like alosetron, duloxetine, ramelteon, tasimelteon, tizanidine, and theophylline. Qelbree can increase blood pressure and heart rate, and it may cause manic episodes in individuals with bipolar disorder. It's important to refrain from driving or operating heavy machinery until it is clear how Qelbree affects the individual, as it may induce sleepiness or fatigue.

Common side effects in children aged 6 to 17 include sleepiness, reduced appetite, tiredness, nausea, vomiting, trouble sleeping, and irritability. In adults, side effects may include insomnia, headache, sleepiness, tiredness, nausea, decreased appetite, dry mouth, and constipation.

For further details on Qelbree, it is recommended to review the full prescribing information and consult with a healthcare provider to determine if Qelbree is suitable for their condition.